Functional dyspepsia, a prevalent disorder with chronic upper abdominal symptoms, is a management challenge, particularly among patients referred to tertiary centers. The literature is dominated by investigations into acid suppressant or Helicobacter pylori eradication regimens. However, many patients with functional dyspepsia do not respond to these measures. Proton pump inhibitors and histamine2 antagonists provide only 7%–10% and 7%–35% therapeutic gains over placebo, respectively.1 Benefits of H pylori treatments are lower (therapeutic gain 6%–14%) than for peptic ulcers.